Clinical Trials Logo

Clinical Trial Summary

This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (50 and 100 mg) compared to placebo for the acute treatment of a single migraine attack.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02828020
Study type Interventional
Source Allergan
Contact
Status Completed
Phase Phase 3
Start date July 22, 2016
Completion date December 14, 2017

See also
  Status Clinical Trial Phase
Completed NCT02848326 - Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention Phase 2/Phase 3
Completed NCT02873221 - An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine Phase 3
Completed NCT03237845 - Safety and Efficacy in Adult Subjects With Acute Migraines Phase 3
Completed NCT03235479 - Safety and Efficacy Study in Adult Subjects With Acute Migraines Phase 3
Completed NCT03461757 - Trial in Adult Subjects With Acute Migraines Phase 3
Completed NCT03266588 - Open Label Safety Study in Acute Treatment of Migraine Phase 2/Phase 3
Completed NCT02867709 - Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine Phase 3